Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNF Inadequate Response
Status:
RECRUITING
Trial end date:
2027-01-15
Target enrollment:
Participant gender:
Summary
This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF) therapy.